Genetic tests may predict which patients with alcohol dependence will benefit from treatment with naltrexone, according to results from a large clinical trial funded by the National Institute on Alcohol Abuse and Alcoholism.
Patients carrying 1 or more copies of the Asp40 allele of the gene encoding the μ opioid receptor drank less and stayed abstinent longer when treated with naltrexone compared with patients who were homozygous for an alternate allele (Asn40) who also received the drug (Anton RF et al. Arch Gen Psychiatry. 2008;65:135-144).
These results are based on genetic analysis of a subset of about 600
patients from the Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence Study. The study, a multisite clinical trial involving more than 1300 patients, compared the effectiveness of various therapies for alcohol dependence.
Kuehn BM. Predicting Naltrexone Response. JAMA. 2008;299(12):1417. doi:10.1001/jama.299.12.1417-c
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: